Autopsy report · NCT01525927

Study of Chemotherapy Prior to Radiotherapy and Chemotherapy in Patients With HPV Associated Cancer of the Oral Cavity

“Principal Investigator left institution. IRB approval lapsed.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months after it had already started.
• Ran for about 1 year 4 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 3 years 9 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Northwell Health

Sponsor type

University, hospital or other

Conditions

Oropharyngeal Neoplasms

Interventions

chemotherapy; radiotherapy; Reduced dose radiotherapy

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Incisional Hernia Outcomes Study Using Parietex Composite Mesh
  “Principal Investigator left institution.” (79% match in meaning)
• Impact of Statins on Cytokine Expression in Pneumonia
  “Investigator left institution.” (75% match in meaning)
• Adherence to Otezla
  “Terminated IRB approval 6/26/2024, study was never initiated or activated” (75% match in meaning)
• Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM
  “Principal Investigator has left the institution” (75% match in meaning)
• Evaluation of a New Surgical Technique for Macular Hole Which Was Not Closed After a Previous Surgery
  “Principal investigator left the institution” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.